FibroBiologics, Inc.
FBLG
$0.8762
$0.00120.14%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 32.30% | -114.41% | -154.12% | -245.63% | -221.91% |
| Total Depreciation and Amortization | 31.12% | 37.16% | 79.58% | 151.58% | 364.89% |
| Total Amortization of Deferred Charges | -- | -100.00% | -100.00% | -99.26% | -79.18% |
| Total Other Non-Cash Items | -120.63% | 292.76% | 678.03% | 1,800.47% | 3,323.77% |
| Change in Net Operating Assets | 13.39% | 336.23% | 795.51% | 1,972.00% | 60.59% |
| Cash from Operations | -85.92% | -74.60% | -44.53% | -61.83% | -57.43% |
| Capital Expenditure | 62.83% | 82.35% | -511.25% | -698.21% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 62.83% | 82.35% | -511.25% | -698.21% | -- |
| Total Debt Issued | -- | -- | -- | -73.30% | -- |
| Total Debt Repaid | -- | -- | -- | -2.22% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -94.58% | 59.81% | 650.60% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 100.00% | -228.21% | -681.67% |
| Cash from Financing | 22.58% | -52.47% | -72.48% | -86.43% | 132.79% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -30.09% | -131.01% | -164.18% | -150.40% | 271.01% |
